Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acorda Therapeutics has completed enrolment for its Phase III clinical trial of Fampridine-SR in multiple sclerosis.
Subscribe to our email newsletter
The trial is designed to evaluate the safety and efficacy of Fampridine-SR in improving walking ability in people with multiple sclerosis.
240 patients were enrolled at 39 clinical trial sites in the US and Canada. The company expects data from the trial in the second quarter of 2008.